New Guideline Includes Immunotherapy

bctt on September 3, 2019

In March, the immunotherapy Tecentriq® (atezolizumab) became the first to be included in NCCN Treatment Guidelines for metastatic breast cancer. It can be used along with Abraxane® (nab-paclitaxel) to treat patients with locally advanced or metastatic triple negative breast cancer who have a tumor that tests positive for PD-L1.

Immunotherapy is a type of biological therapy that uses the body’s immune system to fight cancer. There are many new types of immunotherapies being developed and researchers are actively studying which ones might work in patients with breast cancer.

Below you will find relevant information about MBC treatment guidelines as well as research news and clinical trials on immunotherapy for metastatic breast cancer.

Treatment Guidelines for Metastatic Breast Cancer

bctt on June 2, 2019

A number of organizations bring together panels of experts to develop treatment guidelines for metastatic breast cancer and other forms of cancer. These guidelines can provide a roadmap and touchstone for making treatment decisions.

Below you will find treatment guidelines for metastatic breast cancer developed by the National Comprehensive Cancer Network, UpToDate, European Society for Medical Oncology, National Cancer Institute, and American Society of Clinical Oncology.